Merck to pay $120 mln upfront for cancer drug

Merck & Co Inc is to pay Endocyte Inc $120 million upfront and up to $880 million in performance-based milestones for rights to a candidate compound for ovarian cancer, vintafolide. The compound is being tested with a companion diagnostic.